Yueshan Sun

Dr. Yueshan Sun

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

29 December 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YSYueshan Sun
Yueshan Sun
HLHong Li
Hong Li
LLLei Liu
Lei Liu
XBXiaoqin Bai
Xiaoqin Bai
LWLiping Wu
Liping Wu
YGYuanbiao Guo
Yuanbiao Guo
Mast cell (MC) plays a central role in intestinal permeability; however, few MC-targeting drugs are currently available for protection of the intestinal barrier in clinical practice. A nonfluorinated Lidocaine analog 2-diethylamino-N-2,5-dimethylphenyl acetamide (JM25-1) displays anti-allergic effect, but its impact on MC remains elusive. In this study, we explored whether JM25-1 has therapeutic potential on intestinal barrier defect through stabilizing MC. JM25-1 alleviated release of β-hexosaminidase and cytokine production of MC. The paracellular permeability was redressed by JM25-1 in intestinal epithelial cell monolayers co-cultured with activated MC. In vivo, JM25-1 diminished intestinal mucosal MC amount and cytokine production, especially downregulating the expression of CRHR1, accompanied by an increase of CRHR2. Protective effects appeared in JM25-1-treated stress rats with a recovery of weight and intestinal barrier integrity. Through network pharmacology analysis, JM25-1 showed a therapeutic possibility for irritable bowel syndrome (IBS) with predictive targeting on PI3K/AKT/mTOR signaling. As expected, JM25-1 reinforced p-PI3K, p-AKT, p-mTOR signaling in MC, while the mTOR inhibitor Rapamycin reversed the action of JM25-1 on the expression of CRHR1 and CRHR2. Moreover, JM25-1 successfully remedied intestinal defect and declined MC and CRHR1 expression in rat colon caused by colonic mucus of IBS patients. Our data implied that JM25-1 possessed therapeutic capacity against intestinal barrier defects by targeting the CRH receptors of MC through PI3K/AKT/mTOR signaling.

2 December 2023 in Experimental Cell Research
Verified
Journal Article
Closed access
MHMenghao Hao
Menghao Hao
KZKe Zhong
Ke Zhong
XBXiaoqin Bai
Xiaoqin Bai
SWShiyan Wu
Shiyan Wu
LLLu Li
Lu Li
LWLiping Wu
Liping Wu

4 June 2025 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
YYYang Yu
Yang Yu
MQMingbiao Qiao
Mingbiao Qiao
JLJinbo Liu
Jinbo Liu
YGYuanbiao Guo
Yuanbiao Guo
YSYueshan Sun
Yueshan Sun
Autophagy, a critical cellular process for maintaining homeostasis, involves the degradation and recycling of cellular components through double-membraned vesicles that are transported to lysosomes. This mechanism plays a pivotal role in the immune system by influencing cell fate decisions and functional differentiation. Emerging evidence indicates that autophagy significantly impacts the differentiation and function of T cells and group 3 innate lymphoid cell (ILC3), which are the primary producers of Interleukin-22 (IL-22). IL-22, a key cytokine involved in modulating immune responses and maintaining tissue integrity, is particularly important in combating inflammatory diseases, infections, and cancer. It exerts its effects through a signaling pathway that involves the IL-22R1 and IL-10R2 receptors. Studies have demonstrated that IL-22 can promote autophagy by activating the AMPK pathway and that its intervention can upregulate the expression of autophagy-related genes, underscoring its significant role in the regulation of autophagy. These findings reveal a complex relationship and bidirectional relationship between autophagy and IL-22, highlighting their multifaceted interactions under both physiological and pathological conditions. This review aims to provide a detailed exploration of the dynamic interplay between autophagy and IL-22, with a focus on their mutual regulatory mechanisms, functional significance, and potential for therapeutic interventions. By performing a comprehensive analysis, we sought to clarify the intricate cross talk between autophagy and IL-22, thereby advancing our understanding of their roles in cellular and immune homeostasis and their potential as targets for clinical interventions.

12 February 2026 in Acta Chromatographica
Verified
Journal Article
Open access
XZXi-Qian Zhang
Xi-Qian Zhang
XBXiao-Qin Bai
Xiao-Qin Bai
LLLv-Ye Liu
Lv-Ye Liu
YGYuan-Biao Guo
Yuan-Biao Guo
YSYueshan Sun
Yueshan Sun
2-diethylamino-N-2,5-dimethylphenyl acetamide (JM25-1), a novel anti-inflammatory agent with epithelial barrier protective function, requires comprehensive pharmacokinetic evaluation to support clinical translation. A quantitative analysis method was developed to characterize the pharmacokinetics of JM25-1 in Wistar rats after oral and intraperitoneal ( i.p ) administration. Plasma, obtained via centrifugation and methanol protein precipitation, was analyzed using HPLC-MS/MS. Chromatographic separation was achieved on a Kinetex column embedded with C 18 stationary phase, using a binary-gradient mobile phases consisting of water containing 0.1% formic acid (phase A) and methanol containing 0.1% formic acid (phase B). The flow rate was set at 0.6 mL min −1 with a total run time of 4 min. Mass spectrometric detection was performed by monitoring the m/z transitions of 235.1/86.2 and 235.1/58.1 for JM25-1, 241.2/86.2 and 241.2/58.1 for Lidocaine-d6 (used as internal standard) in the electrospray ionization positive mode. The method exhibited excellent linearity over concentration ranges of 1–200 ng mL −1 ( r 2 = 0.9998). All validation parameters, including specificity, extraction recovery (89.65–98.44%), matrix effect (absolute: 97.22–99.82%; relative: <15%), accuracy (87.93–104.18%), and precision (intra- and inter-day RSD ≤7.26%), met bioanalytical acceptance criteria. Stability assessments confirmed that JM25-1 remained stable under all tested conditions. Pharmacokinetically, oral administration showed rapid absorption ( t max = 10 min) but significantly lower systemic exposure compared to i.p , resulting in low bioavailability. This study developed a rapid, sensitive, and reproducible HPLC-MS/MS method for JM25-1 quantification in rat plasma, and the validated method was successfully applied to the pharmacokinetic study of JM25-1 following oral and i.p administration.

20 May 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
NPNingjing Pu
Ningjing Pu
JXJuan Xiong
Juan Xiong
YSYueshan Sun
Yueshan Sun
KLKe Li
Ke Li
YGYuanbiao Guo
Yuanbiao Guo
Objective: Our objective was to investigate the association between serum phosphorus levels and 28-day mortality in patients with bloodstream infection (BSI), and to explore whether this association persists after adjusting for renal function and clinical severity. Methods: This retrospective cohort study included 214 BSI patients. Patients were divided into hyperphosphatemia (≥2.2 mmol/L, n = 15) and control (<2.2 mmol/L, n = 199) groups. To address the small sample size and potential separation, multivariate Firth’s penalized likelihood regression was utilized to evaluate the association with 28-day mortality. Restricted cubic spline regression explored the continuous relationship. Fine–Gray competing risk models, 1000-resample bootstrapping, and E-value analyses were conducted to ensure the robustness of the observed associations. Results: The 28-day mortality rate was significantly higher in the hyperphosphatemia group (80.0% vs. 39.7%, p = 0.005). After adjusting for age, sex, and estimated glomerular filtration rate (eGFR), hyperphosphatemia remained significantly associated with higher observed 28-day mortality (OR = 4.46, 95% CI: 1.36–18.54, p = 0.012). This association remained robust even after further adjustment for septic shock (OR = 4.74, 95% CI: 1.30–21.64, p = 0.017). Analyzed continuously, each 0.5 mmol/L increase in serum phosphorus was associated with 34% higher odds of mortality (OR = 1.34, 95% CI: 1.07–1.74, p = 0.01). Spline analysis confirmed a nonlinear relationship with a threshold at 2.2 mmol/L. Kaplan–Meier analysis demonstrated a severity-driven survival separation in the hyperphosphatemia group (Log-rank p < 0.001). The association remained highly robust after adjusting for early discharge competing risks (sHR = 4.62, p < 0.001) and in bootstrap validation (median OR = 4.80). Conclusions: Serum phosphorus ≥ 2.2 mmol/L is associated with higher observed mortality in BSI patients, an association that remained evident after adjusting for renal function and clinical severity, including septic shock. However, given the small hyperphosphatemia subgroup (n = 15), limited statistical stability, and the potential for residual confounding, these findings should be considered hypothesis-generating rather than definitive, requiring prospective validation in larger, adequately powered cohorts. Rather than a definitive triage tool, serum phosphorus may serve as a simple, adjunctive marker for early metabolic assessment in severe infections.